Proceedings of the Guideline Workshop 2019: Strategies for the Optimization of Guideline Processes in Diabetes,Cardiovascular Diseases,and Kidney Diseases

Abstract

The Guideline Workshop 2019, held in October 2019 in Munich, Germany, had the purpose of facilitating discussion on strategies for optimization of guideline processes in diabetes among a group of representatives of renown national and international societies in the field of diabetes, cardiology, and nephrology. Results of this panel's discussions are presented in this article and comprise a variety of suggestions for improving the quality and usability of guidelines, as well as to accelerate the development and responsiveness of guidelines to newly published, relevant data from clinical trials such as cardiovascular outcome trials in diabetes mellitus. These include, but are not limited to, recommendations to optimize presentation of content in guidelines, use of the Grading of Recommendations Assessment, Development, and Evaluation approach to rating the quality of evidence to harmonize guidelines, and utilization of digital health technologies to accelerate, streamline, and optimize communication on relevant data and development of clinical guidelines and necessary updates, while reducing costs. Recognizing that achieving alignment in guideline development among various medical organizations will be a long-term process, representatives from cross-sectional medical organizations relevant to cardio/renal metabolic disease and experts in guideline methodology will work together in the future. Among other activities, it is planned to continue the activity and organize a Guideline Workshop in 2020.

Preface

Discussion, as described in this article, was conducted by all participants from the perspective of their respective medical associations. Participants of the Guideline Workshop 2019 were as follows: F.B. (American Society of Nephrology), A.C. (Italian Online Guidelines, Associazione Medici Diabetologi), M.C. (Kidney Disease: Improving Global Outcomes), F.C. (European Society of Cardiology or ESC), J.G. (American Diabetes Association or ADA), M.K. (Deutsche Diabetes Gesellschaft), S.K. (Preventive Cardiovascular Nurses Association), M.K. (American College of Cardiology), N.M. (ESC), P.N. (American Heart Association), L.R. (ESC), H.R. (American Association of Clinical Endocrinologists), E.S. (Forschergruppe Diabetes, e.V.), and P.O.V. (MAGIC Evidence Ecosystem Foundation [www.MAGICproject.org]). Initiator of the Guideline Workshop: O.S. (Forschergruppe Diabetes, e.V.).